S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
NASDAQ:ALLO

Allogene Therapeutics Insider Trades

$11.78
-1.50 (-11.30%)
(As of 01/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.77
$13.03
50-Day Range
$11.96
$19.37
52-Week Range
$11.54
$39.12
Volume
2.50 million shs
Average Volume
2.05 million shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.71

Allogene Therapeutics (NASDAQ:ALLO) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
26.30%

Number Of
Insiders Buying
(Last 12 Months)
1

Amount Of
Insider Buying
(Last 12 Months)
$1.95 M

Number Of
Insiders Selling
(Last 12 Months)
4

Amount Of
Insider Selling
(Last 12 Months)
$1.58 M

Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Get ALLO Insider Trade Alerts

Want to know when executives and insiders are buying or selling Allogene Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.


Allogene Therapeutics (NASDAQ ALLO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2022Arie BelldegrunDirectorBuy155,039$12.60$1,953,491.40  
10/1/2021Rafael AmadoCMOSell11,507$24.35$280,195.45  
9/9/2021Owen N. WitteDirectorSell5,000$25.54$127,700.00221,182  
8/20/2021Owen N WitteDirectorSell10,000$23.47$234,700.00  
8/16/2021Veer BhavnagriGeneral CounselSell5,000$21.00$105,000.00  
7/15/2021Veer BhavnagriGeneral CounselSell5,000$21.55$107,750.00426,353  
6/9/2021Owen N WitteDirectorSell9,969$25.05$249,723.45236,182  
5/18/2021Veer BhavnagriGeneral CounselSell5,000$30.00$150,000.00426,353  
4/15/2021Veer BhavnagriGeneral CounselSell10,000$32.05$320,500.00431,353  
1/14/2021Eric Thomas SchmidtCFOSell15,000$30.77$461,550.0078,916  
10/15/2020Eric Thomas SchmidtCFOSell15,000$40.49$607,350.00  
10/13/2020Alison MooreInsiderSell35,264$42.00$1,481,088.00
10/9/2020Alison MooreInsiderSell44,574$41.00$1,827,534.00122,745  
10/7/2020Rafael AmadoCMOSell16,538$39.40$651,597.20111,677  
10/6/2020Alison MooreInsiderSell44,574$40.00$1,782,960.00161,536  
10/6/2020Veer BhavnagriGeneral CounselSell10,000$40.00$400,000.00363,902  
10/1/2020Veer BhavnagriGeneral CounselSell25,000$36.52$913,000.00378,902  
9/21/2020Eric Thomas SchmidtCFOSell15,000$35.30$529,500.00  
8/3/2020Veer BhavnagriGeneral CounselSell31,553$36.89$1,163,990.17385,455  
6/29/2020Group Holdings (Sbs) Advis TpgMajor ShareholderSell24,904$43.27$1,077,596.08  
6/26/2020Group Holdings (Sbs) Advis TpgMajor ShareholderSell500$44.01$22,005.00  
6/24/2020Group Holdings (Sbs) Advis TpgMajor ShareholderSell15,269$43.93$670,767.17  
6/22/2020Group Holdings (Sbs) Advis TpgMajor ShareholderSell172,425$42.83$7,384,962.75  
6/19/2020Group Holdings (Sbs) Advis TpgMajor ShareholderSell47,767$42.04$2,008,124.68  
6/17/2020Group Holdings (Sbs) Advis TpgMajor ShareholderSell87,319$42.18$3,683,115.42  
6/15/2020Group Holdings (Sbs) Advis TpgMajor ShareholderSell129,154$42.14$5,442,549.56  
6/4/2020Arie BelldegrunDirectorBuy146,382$43.00$6,294,426.00
6/3/2020Group Holdings (Sbs) Advis TpgMajor ShareholderSell487,402$47.40$23,102,854.80  
3/16/2020Alison MooreInsiderSell3,750$19.19$71,962.50  
3/16/2020David D ChangCEOSell20,335$19.31$392,668.852,215,426  
3/16/2020Eric Thomas SchmidtCFOSell5,450$19.73$107,528.5047,257  
9/18/2019Alison MooreInsiderSell48,827$32.11$1,567,834.97
7/30/2019Alison MooreInsiderSell48,827$29.44$1,437,466.88  
6/3/2019Alison MooreInsiderSell48,828$26.76$1,306,637.28  
5/14/2019Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,918,755$29.38$56,373,021.90  
10/15/2018Arie BelldegrunDirectorBuy35,000$18.00$630,000.00  
10/15/2018David D ChangInsiderBuy40,000$18.00$720,000.00  
10/15/2018Group Holdings (Sbs) Advis TpgMajor ShareholderBuy675,000$18.00$12,150,000.00  
(Data available from 1/1/2013 forward)












Allogene Therapeutics (NASDAQ:ALLO) Insider Trade Frequently Asked Questions

Who is on Allogene Therapeutics's Insider Roster?

The list of insiders at Allogene Therapeutics includes Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Rafael Amado, and Veer Bhavnagri.Learn more on ALLO's insiders

What percentage of Allogene Therapeutics stock is owned by insiders?

26.30% of Allogene Therapeutics stock is owned by insiders. Learn more on ALLO's insider holdings

Which Allogene Therapeutics insiders have been buying company stock?

The following insider purchased Allogene Therapeutics stock in the last 24 months: Arie Belldegrun ($8,247,917.40).

How much insider buying is happening at Allogene Therapeutics?

Insiders have purchased a total of 301,421 Allogene Therapeutics shares in the last 24 months for a total of $8,247,917.40 bought.

Which Allogene Therapeutics insiders have been selling company stock?

The following insiders have sold Allogene Therapeutics stock in the last 24 months: Alison Moore ($5,163,544.50), David D Chang ($392,668.85), Eric Thomas Schmidt ($1,705,928.50), Group Holdings (Sbs) Advis Tpg ($43,391,975.46), Owen N Witte ($484,423.45), Rafael Amado ($931,792.65), and Veer Bhavnagri ($3,160,240.17).

How much insider selling is happening at Allogene Therapeutics?

Insiders have sold a total of 1,308,254 Allogene Therapeutics shares in the last 24 months for a total of $55,358,273.58 sold.

This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.